{"gene":"CCR3","run_date":"2026-06-09T22:57:17","timeline":{"discoveries":[{"year":1996,"finding":"CCR3, when co-expressed with CD4 on otherwise non-permissive cells, functions as a co-receptor for entry by a restricted subset of primary HIV-1 isolates; binding of the CCR3 ligand eotaxin inhibits HIV-1 infection, and co-receptor usage depends on the V3 region of gp120.","method":"Cell-based infectivity assay with CCR3-transfected cell lines co-expressing CD4; ligand competition experiment","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — functional reconstitution in transfected cells, ligand competition, replicated independently in the same issue (PMID:8674120)","pmids":["8674119","8674120"],"is_preprint":false},{"year":1997,"finding":"CCR3 and CCR5 are both expressed on brain microglia and serve as co-receptors for HIV-1 infection of these CNS cells; the CCR3 ligand eotaxin and anti-CCR3 antibody inhibited HIV-1 infection of microglia.","method":"Primary microglial infection assay; antibody/ligand blocking experiments","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct infection assay with blocking antibody and ligand competition in primary CNS cells, replicated across multiple papers","pmids":["9024664"],"is_preprint":false},{"year":1997,"finding":"CCR3 is selectively expressed on human Th2 (but not Th1) cells; eotaxin stimulation of CCR3+ T cells induces intracellular calcium increase and chemotaxis.","method":"Anti-CCR3 antibody-based cell isolation; intracellular calcium measurement; chemotaxis assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (antibody isolation, Ca2+ flux, chemotaxis), replicated in independent lab (PMID:9480044)","pmids":["9302298","9480044"],"is_preprint":false},{"year":1997,"finding":"CCR3 function (eotaxin binding and CCR3-mediated calcium mobilization and eosinophil chemotaxis) is markedly sensitive to small changes in extracellular pH and ionic strength (NaCl concentration) within physiological and near-physiological ranges.","method":"Radioligand binding assay; Ca2+ mobilization assay; in vitro eosinophil chemotaxis assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays in a single lab demonstrating pH/ionic-strength sensitivity","pmids":["9353270"],"is_preprint":false},{"year":1999,"finding":"IFN-γ treatment of human neutrophils induces CCR3 (and CCR1) mRNA and surface expression, enabling functional chemotactic responses to eotaxin; an anti-CCR3 monoclonal antibody (7B11) blocked this eotaxin-induced chemotaxis.","method":"RT-PCR; radioligand binding; in vitro chemotaxis assay with blocking mAb","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (mRNA, binding, chemotaxis + antibody block), single lab","pmids":["9886422"],"is_preprint":false},{"year":1999,"finding":"Chemokine-induced eosinophil degranulation (eosinophil-derived neurotoxin release) is mediated exclusively through CCR3; non-CCR3 ligands that induce calcium influx do not induce degranulation, and anti-CCR3 antibody significantly inhibited CCR3-ligand-induced degranulation.","method":"Ca2+ flux assay; RIA for eosinophil-derived neurotoxin; antibody blocking experiments on purified eosinophils","journal":"The Journal of allergy and clinical immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal assays (Ca2+ flux, degranulation, blocking antibody) in purified primary cells, specificity rigorously tested with multiple ligands","pmids":["10984371"],"is_preprint":false},{"year":1999,"finding":"Met-RANTES acts as an antagonist of human eosinophil effector functions (Ca2+ transients, actin polymerization, reactive oxygen species release) through CCR1 preferentially over CCR3; eotaxin-induced responses via CCR3 were only partially blocked at concentrations that fully blocked RANTES/MCP-3 responses.","method":"Ca2+ flux assay; actin polymerization assay; reactive oxygen species assay; dose-response antagonism with Met-RANTES on purified eosinophils","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple effector function assays with a pharmacological antagonist, single lab","pmids":["9394815"],"is_preprint":false},{"year":2000,"finding":"The N-terminal region of CCR3 (residues 1–35, especially the DDYY-containing central region around residues 8–23) is the primary binding surface for eotaxin; the N-loop, 3(10)-helical turn, and β2-β3 hairpin of eotaxin form the complementary receptor-binding groove.","method":"Synthetic peptide binding screens; NMR spectroscopy (1H-15N HSQC, 2D/3D homonuclear NMR, 15N-filtered TOCSY); dissociation constant measurement","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structural characterization with peptide binding affinities, single lab but rigorous structural approach","pmids":["10859315"],"is_preprint":false},{"year":2000,"finding":"CCR3 is functionally expressed on human platelets; eotaxin activates platelets via CCR3, inducing Ca2+ signals, aggregation, and granule release; these responses are partially dependent on secondary ADP release and are inhibited by cleavage of heparan/chondroitin sulfate on the platelet surface.","method":"RT-PCR; flow cytometry; immunoprecipitation/Western blot; Ca2+ measurement; aggregation and granule release assays; glycosaminoglycan cleavage experiments","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods confirming functional CCR3 on platelets, single lab","pmids":["11110672"],"is_preprint":false},{"year":2000,"finding":"CCL11 (eotaxin) induces CCR3-dependent smooth muscle cell (SMC) chemotaxis and migration; anti-CCR3 antibody (but not anti-CCR2) blocked SMC migration; CCR3 is upregulated in medial SMCs after arterial injury in a pattern consistent with a migratory phenotype.","method":"RT-PCR; Western blot; flow cytometry; Boyden chamber chemotaxis assay; scrape-wound assay; antibody blocking; in vivo mouse femoral artery injury model with immunostaining","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal in vitro assays plus in vivo validation, antibody specificity controls","pmids":["15130922"],"is_preprint":false},{"year":2001,"finding":"CCR3 is functionally expressed on airway epithelial cells; eotaxin stimulates intracellular Ca2+ flux and tyrosine phosphorylation of cellular proteins via epithelial CCR3; these signals are blocked by anti-CCR3 mAb (7B11) or pertussis toxin, and 125I-eotaxin binding confirms expected ligand specificity.","method":"Northern blot; Western blot; flow cytometry; Ca2+ flux assay; tyrosine phosphorylation assay; radioligand binding; pertussis toxin treatment; antibody blocking","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (mRNA, protein, Ca2+ signaling, phosphorylation, radioligand binding, pharmacological/antibody blocking) in primary and cell-line models","pmids":["11160184"],"is_preprint":false},{"year":2001,"finding":"IL-3 induces dose- and time-dependent down-regulation of CCR3 surface expression and mRNA in human eosinophils; this down-regulation is prevented by anti-IL-3 antibody and by phenylarsine oxide (an inhibitor of receptor internalization), and is partially inhibited by the PI3K inhibitor wortmannin, indicating a distinct internalization mechanism from eotaxin-induced down-regulation.","method":"Flow cytometry; RT-PCR; Ca2+ flux assay; pharmacological inhibition (wortmannin, phenylarsine oxide); blocking antibody","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple assays (flow cytometry, mRNA, pharmacological inhibitors) in primary eosinophils, single lab","pmids":["11544337"],"is_preprint":false},{"year":2001,"finding":"Eotaxin induces differentiation of eosinophils from CD34+ cord blood progenitor cells via CCR3 (which is expressed and functional on these progenitors); this differentiation is IL-3-, IL-5-, and GM-CSF-independent, and Th2 cytokines up-regulate CCR3 surface expression on progenitors while IL-12/IFN-γ decreases it.","method":"In situ RT-PCR; immunostaining; flow cytometry; Ca2+ mobilization assay; in vitro eosinophil differentiation culture with neutralizing antibodies","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods confirming CCR3 function in progenitor differentiation, single lab","pmids":["12496441"],"is_preprint":false},{"year":2003,"finding":"CXCR3 ligands (CXCL9, CXCL10, CXCL11) inhibit CCR3-mediated functional responses (chemotaxis and Ca2+ flux) in human eosinophils and CCR3 transfectants induced by all three eotaxins; CXCL11 is the most efficacious antagonist. CCR3-CCR1 chimeric receptor studies revealed that CCL11 and CXCL11 share overlapping binding sites within CCR3 extracellular loops. Additionally, CCL11 binds with high affinity to CXCR3 (acting as a potential decoy receptor).","method":"Ca2+ flux assay; eosinophil chemotaxis assay; CCR3-CCR1 chimeric receptor constructs; radioligand binding","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — chimeric receptor mutagenesis combined with functional assays (Ca2+ flux, chemotaxis, binding) establishing overlapping binding sites","pmids":["12884299"],"is_preprint":false},{"year":2003,"finding":"CCR3 ligation by eotaxin/CCL11 induces apoptosis in IL-2/IL-4-stimulated B cells via upregulation of CD95 and CD95L, triggering a caspase cascade; this apoptotic effect is distinct from chemotaxis (CCR3 ligation does not induce chemotaxis or adhesion in these cells).","method":"Flow cytometry; apoptosis assays; cytochrome c release measurement; caspase activity assays; CD95/CD95L expression analysis in primary B cells and B cell lines","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional and mechanistic assays in primary cells, single lab","pmids":["12902471"],"is_preprint":false},{"year":2004,"finding":"CCR3 activation by eotaxin in bronchial epithelial cells (NCI-H292) leads to transactivation of EGFR (tyrosine phosphorylation of EGFR); EGFR inhibition (AG1478) blocks CCR3-induced MAP kinase phosphorylation and IL-8 production.","method":"Tyrosine phosphorylation assay; EGFR inhibitor (AG1478) treatment; MAP kinase phosphorylation assay; IL-8 ELISA","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection of CCR3-EGFR crosstalk with multiple downstream readouts, single lab","pmids":["15219825"],"is_preprint":false},{"year":2005,"finding":"Eotaxin and CCR3-deficient mice show profound reduction of allergen-induced eosinophil recruitment to the airway lumen and loss of organized peribronchial/perivascular eosinophil accumulation; eotaxin-1/2 double-knockout approaches CCR3-deficiency levels, demonstrating a hierarchical and synergistic role for multiple CCR3 ligands in pulmonary eosinophilia.","method":"Genetic knockout mouse models (eotaxin-1, eotaxin-2, eotaxin-1/2 double KO, CCR3 KO); OVA-induced experimental asthma model; bronchoalveolar lavage analysis; tissue eosinophil counting","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — rigorous genetic epistasis with multiple knockout combinations, established experimental asthma model, multiple tissue compartments analyzed","pmids":["16210640"],"is_preprint":false},{"year":2005,"finding":"CCR3 signaling mediates recruitment of eosinophils specifically to airway nerves (not overall tissue eosinophilia); CCR3 antagonist (GW701897B) prevented eosinophil clustering around nerves, preserved inhibitory M2 muscarinic receptor function, and abrogated airway hyperresponsiveness. Eotaxin is produced by airway parasympathetic neurons and is upregulated by IL-4 and IL-13.","method":"In vivo guinea pig antigen challenge model; CCR3 antagonist treatment; vagal stimulation assay; M2R function assay; immunostaining; cultured airway neurons + neuroblastoma cells with cytokine stimulation","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo pharmacological intervention with neurophysiological readouts, in vitro mechanistic follow-up in primary neurons","pmids":["16374515"],"is_preprint":false},{"year":2005,"finding":"CCR3 is functionally expressed on asthmatic airway smooth muscle cells (ASMC) at higher levels than in non-asthmatic subjects; TNF-α increases CCR3 surface expression; eotaxin induces Ca2+ mobilization and significant chemotaxis of ASMC via CCR3.","method":"RT-PCR; FACS; Ca2+ assay; in vitro Boyden chamber chemotaxis assay; TNF-α stimulation","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays confirming CCR3 activity in primary ASMC, single lab","pmids":["16081847"],"is_preprint":false},{"year":2006,"finding":"CCR3 activation in airway epithelial cells by eotaxins (CCL11, CCL24, CCL26) drives wound closure, cell proliferation, and chemotaxis; CCL11 also up-regulates profibrogenic molecules (FGF-1, FGF-5) and multiple CC/CXC chemokines; all effects are selectively inhibited by a CCR3 antagonist.","method":"In vitro wound repair assay; fluorometric proliferation and chemotaxis assays; pathway-specific cDNA arrays; CCR3 antagonist treatment","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays with pharmacological specificity control, single lab","pmids":["16920975"],"is_preprint":false},{"year":2006,"finding":"IL-13 transgenic lung overexpression-driven eosinophil recruitment and airway remodeling (mucus metaplasia, collagen deposition) require CCR3; CCR3-deficient mice crossed with IL-13 transgenics show 98% reduction in lung eosinophils and marked attenuation of remodeling, correlating with changes in pulmonary TGF-β1 and protease expression.","method":"Genetic cross of IL-13 lung-inducible transgenic mice with CCR3-deficient mice; histological and biochemical analysis of remodeling markers; eosinophil-deficient (ΔdblGATA) mouse controls","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 / Strong — rigorous genetic epistasis with multiple knockout backgrounds, quantitative histology and molecular markers","pmids":["17148674"],"is_preprint":false},{"year":2007,"finding":"Transmembrane residues Tyr-41, Tyr-113, and Glu-287 of CCR3 are critical for both antagonist (UCB35625) binding and receptor activation by CCL11/eotaxin; mutation Y113A abolishes antagonist binding and converts UCB35625 from antagonist to agonist; a novel specific CCR3 agonist (CH0076989) interacts with the same transmembrane residues and does not require the CCR3 N-terminus.","method":"Site-directed mutagenesis; CCR3-CCR1 chimeric receptor constructs; cell-based chemotaxis assay; Ca2+ flux assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — active-site mutagenesis with multiple mutants, chimeric receptors, and functional assays; single lab but multiple orthogonal approaches","pmids":["17635911"],"is_preprint":false},{"year":2009,"finding":"CCR3 is specifically expressed on choroidal neovascular endothelial cells in human AMD; genetic or pharmacological targeting of CCR3 or its eotaxin ligands inhibits injury-induced CNV in mice; CCR3 blockade directly inhibits endothelial cell proliferation and is uncoupled from eosinophil/mast cell inflammation.","method":"Immunohistochemistry on human AMD tissue; CCR3 gene knockout and pharmacological inhibition in mouse CNV models; endothelial proliferation assay; quantum dot in vivo imaging; comparison with eosinophil- and mast cell-deficient mice","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic and pharmacological CCR3 targeting, human tissue validation, mechanistic dissection using cell-type-deficient mice","pmids":["19525930"],"is_preprint":false},{"year":2011,"finding":"CCL11 activates CCR3 on anaplastic large cell lymphoma (ALCL) cells in an autocrine manner, promoting cell survival via ERK1/2 phosphorylation and upregulation of anti-apoptotic proteins Bcl-xL and survivin; ERK inhibition completely blocked CCL11-promoted survival.","method":"Cell survival and proliferation assays; ERK1/2 phosphorylation (Western blot); anti-apoptotic protein expression; ERK inhibitor treatment; in vivo tumor growth assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple mechanistic assays (signaling, survival, in vivo) in cell lines, single lab","pmids":["21406396"],"is_preprint":false},{"year":2013,"finding":"CCR3-mediated secretion of eosinophil-associated RNases (EARs) in mouse and human eosinophils requires Gαi-dependent signaling through PI3K, ERK, and p38 MAPK; β1 and β2 integrins are also required, with cell spreading being obligatory for EAR secretion.","method":"RNase activity assay on primary mouse and human eosinophils; specific pathway inhibitors (PI3K, ERK, p38 MAPK inhibitors); integrin-blocking antibodies; microscopy for cell adhesion/spreading","journal":"Allergy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection of signaling pathway in primary cells from two species, single lab","pmids":["23742707"],"is_preprint":false},{"year":2013,"finding":"CCL26 (eotaxin-3) induces CCR3 signaling in human dermal fibroblasts (which express CCR3 abundantly), resulting in intracellular Ca2+ mobilization, enhanced fibroblast migration, and wound repair capacity, but no proliferation; this provides a CCR3-mediated epidermis-to-dermis communication pathway in atopic skin inflammation.","method":"Flow cytometry and immunofluorescence for CCR3 on fibroblasts; Ca2+ mobilization assay; cell migration and repair assays; cell proliferation assay; real-time PCR for CCL26","journal":"Journal of dermatological science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays in primary fibroblasts, single lab","pmids":["23702389"],"is_preprint":false},{"year":2014,"finding":"Tyrosine sulfation of CCR3 N-terminal residues (specifically two sulfotyrosines in residues 8–23) dramatically enhances binding to CCL11/eotaxin-1; structural analysis reveals sulfotyrosine residues form hydrophobic, salt bridge, and cation-π interactions with conserved residues in CC chemokines. The orientation of CCR3 N-terminus relative to the chemokine differs substantially from CXC chemokine receptor complexes.","method":"NMR structure determination of CCL11 bound to sulfo-CCR3(8-23) peptide; functional receptor activity assays confirming intact CCR3 sulfation; binding affinity measurement","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Strong — NMR structure with functional validation of sulfation, mechanistic insights into receptor-ligand recognition","pmids":["25450766"],"is_preprint":false},{"year":2014,"finding":"Eotaxin-1 (CCL11) promotes prostate cancer cell invasion and migration via the CCR3-ERK pathway, leading to upregulation of MMP-3; siRNA knockdown of CCR3 inhibits invasion and attenuates eotaxin-1-induced ERK1/2 activation and MMP-3 expression; MEK inhibition (U0126) similarly suppresses invasion.","method":"siRNA knockdown of CCR3; invasion/migration assays; ERK1/2 phosphorylation (Western blot); MMP-3 mRNA (RT-PCR) and protein (ELISA); MEK inhibitor (U0126)","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA KD with multiple functional and signaling readouts, pharmacological pathway validation, single lab","pmids":["24604010"],"is_preprint":false},{"year":2016,"finding":"CCL7 interacts with CCR3 in colon cancer cells to promote cellular proliferation, invasion, and migration via the ERK and JNK signaling pathways; CCL7-overexpressing cells formed faster ectopic tumors and developed liver/lung metastases in orthotopic mouse models.","method":"CCL7-overexpressing cell lines; in vitro proliferation, invasion, and migration assays; ectopic and orthotopic mouse models; signaling pathway analysis (ERK, JNK)","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo mechanistic experiments, single lab","pmids":["27167205"],"is_preprint":false},{"year":2017,"finding":"CCL8 binds directly to CCR3 with a KD of ~1.2 × 10−7 M (measured by quartz crystal microbalance); CCL8 induces CCR3 internalization in vivo and has a weaker chemotactic effect compared to CCL11 and CCL24 on CCR3-expressing cells.","method":"Quartz crystal microbalance (QCM) binding assay; receptor internalization assay (flow cytometry); chemotaxis assay","journal":"BMC immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding measurement plus functional confirmation, single lab, biophysical approach","pmids":["29281969"],"is_preprint":false},{"year":2018,"finding":"A peptide nanoparticle CCR3 antagonist (R321) binds directly to CCR3, inhibits only the early phase of ERK1/2 activation (not the late β-arrestin-associated phase), promotes CCR3 internalization and degradation (biased antagonism), and blocks eosinophil recruitment and airway hyperresponsiveness in a mouse asthma model.","method":"Dynamic light scattering; NMR binding analysis; flow cytometry; confocal microscopy; ERK1/2 Western blot (time-course); in vivo triple-allergen mouse asthma model","journal":"The Journal of allergy and clinical immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct binding demonstrated by NMR, biased signaling established by time-resolved Western blot, in vivo validation in disease model","pmids":["29778505"],"is_preprint":false},{"year":2021,"finding":"Cholesterol acts as a dose-dependent positive allosteric modulator of CCR3 function: increasing cholesterol concentration enhances CCR3 affinity for CCL11 (in both SMALPs and proteoliposomes), and this heightened receptor activation directly increases GTPase activity of the associated Gαi3 protein.","method":"Recombinant CCR3 production in E. coli; reconstitution into SMALPs and proteoliposomes; ligand affinity measurement; Gαi3 GTPase activity assay","journal":"Frontiers in molecular biosciences","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro biochemical reconstitution with functional G-protein assay, single lab","pmids":["34490352"],"is_preprint":false},{"year":2022,"finding":"Cryo-EM structure of CCR3 in the apo state reveals that interactions around intracellular loop 2 (ICL2) of CCR3 are critical and conserved for G-protein activation; these interactions play a more critical role in G-protein coupling than those around ICL3.","method":"Cryo-electron microscopy; structure determination; functional mutagenesis experiments","journal":"Cell discovery","confidence":"High","confidence_rationale":"Tier 1 / Moderate — cryo-EM structure complemented by functional mutagenesis experiments, rigorous structural biology approach","pmids":["35570218"],"is_preprint":false},{"year":2022,"finding":"Conditional knockout of bone marrow CCR3 in mice reduces eosinophilic inflammation and Th2 immune response in an OVA-induced allergic rhinitis model; this is mechanistically linked to inhibition of the PI3K/AKT signaling pathway downstream of CCR3.","method":"Cre-LoxP conditional knockout; OVA-induced AR mouse model; PI3K/AKT pathway inhibitor (Ly294002); histopathology; eosinophil counting; cytokine ELISA","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with pharmacological pathway confirmation, single lab","pmids":["35354939"],"is_preprint":false},{"year":2022,"finding":"The CCL24/CCR3 axis stimulates M2 macrophage polarization and cardiac fibroblast activation via CCR3's G protein-coupled receptor function; blocking CCL24 prevents Ang II-induced cardiac hypertrophy and fibrosis; in vitro experiments confirmed CCL24 promotes activation and migration of cardiac fibroblasts via CCR3.","method":"Co-IP; ChIP; CCL24 antibody blockade in vivo (Ang II mouse model); single-cell CyTOF; in vitro fibroblast activation/migration assays; immunofluorescence co-localization","journal":"Cell biology and toxicology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro mechanistic experiments with multiple methods, single lab","pmids":["36131165"],"is_preprint":false},{"year":2023,"finding":"CCR3-expressing T cells in the periphery mediate age-related cognitive decline and neuroinflammation; CCR3 inhibition prevents infiltration of CCR3+ T cells across the blood-brain barrier, reducing neuroinflammation. The pro-cognitive benefit of CCR3 inhibition is not due to direct action on CNS-resident cells.","method":"CCR3 inhibition in aged mice; behavioral cognitive testing; T-cell infiltration analysis; blood-brain barrier assessment","journal":"Communications biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo pharmacological inhibition with mechanistic dissection distinguishing peripheral vs. central effects, single lab","pmids":["36934154"],"is_preprint":false},{"year":2023,"finding":"IgE directly promotes eosinophil migration in chronic rhinosinusitis by upregulating CCR3 expression on eosinophils; this effect is mediated through CD23 (FcεRII) on eosinophils, as lumiliximab (anti-CD23) restrains IgE-induced CCR3-dependent migration.","method":"Flow cytometry; immunohistochemistry/immunofluorescence; functional eosinophil migration assay; antibody blockade (omalizumab, lumiliximab)","journal":"The Journal of allergy and clinical immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional migration assay with antibody blocking, mechanistic link between IgE/CD23 and CCR3, single lab","pmids":["37922997"],"is_preprint":false},{"year":2023,"finding":"CCR3 mediates CCL7-induced neuronal hyperexcitability and ERK activation in trigeminal ganglion neurons; selective CCR3 antagonist (intra-TG injection) alleviates trigeminal neuropathic pain and reduces ERK phosphorylation; CCR3 is co-expressed with CCR2 on TG neurons.","method":"Real-time qPCR; immunofluorescence; Western blot (ERK phosphorylation); whole-cell patch clamp recording; selective receptor antagonists (intra-TG injection); behavioral pain testing","journal":"Molecular pain","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — electrophysiology, pharmacological antagonism, and in vivo pain behavioral readouts, single lab","pmids":["36998150"],"is_preprint":false}],"current_model":"CCR3 is a Gαi-coupled, seven-transmembrane CC chemokine receptor whose N-terminal sulfotyrosine residues (and extracellular loop 2) mediate high-affinity binding to eotaxins (CCL11, CCL24, CCL26) and other CC chemokines; upon ligand binding it couples to Gαi3 (allosterically potentiated by cholesterol), activates PI3K, ERK, p38 MAPK, and intracellular calcium signaling to drive eosinophil degranulation, chemotaxis, and EAR secretion; it is also expressed on Th2 lymphocytes, mast cells, airway epithelial and smooth muscle cells, dendritic cells, platelets, and vascular smooth muscle cells—mediating migration, wound repair, and remodeling in each—and functions as an HIV-1 co-receptor on CD4+ cells and microglia; transmembrane residues Tyr-41, Tyr-113, and Glu-287 are critical for both agonist activation and small-molecule antagonist binding, with ICL2 contacts being essential for G-protein coupling as revealed by cryo-EM."},"narrative":{"mechanistic_narrative":"CCR3 is a Gαi-coupled CC chemokine receptor that serves as the central effector receptor for eotaxins (CCL11/CCL24/CCL26) and related CC chemokines, driving eosinophil chemotaxis, degranulation, and tissue accumulation that underlie allergic and remodeling pathology [PMID:10984371, PMID:16210640]. High-affinity ligand engagement is governed by the receptor N-terminus: residues 1–35, and particularly two sulfotyrosines in the DDYY-containing region around residues 8–23, form the primary chemokine-binding surface through hydrophobic, salt-bridge, and cation-π contacts that are oriented distinctly from CXC-receptor complexes [PMID:10859315, PMID:25450766]. Agonist activation and small-molecule antagonist binding both converge on transmembrane residues Tyr-41, Tyr-113, and Glu-287, where the Y113A mutation can convert an antagonist into an agonist, while intracellular loop 2 contacts revealed by cryo-EM are the critical determinant of G-protein coupling [PMID:17635911, PMID:35570218]; cholesterol acts as a positive allosteric modulator that enhances CCL11 affinity and stimulates Gαi3 GTPase activity [PMID:34490352]. Downstream, CCR3 signals through Gαi-dependent PI3K, ERK, and p38 MAPK, with cell spreading via β1/β2 integrins required for eosinophil RNase secretion, and EGFR transactivation contributing to MAP-kinase and IL-8 responses in epithelium [PMID:23742707, PMID:15219825]. Beyond eosinophils, functional CCR3 is expressed on Th2 cells, platelets, airway epithelial and smooth muscle cells, dermal fibroblasts, and vascular endothelium, where it mediates migration, wound repair, fibrosis, and neovascularization [PMID:9302298, PMID:9480044, PMID:15130922, PMID:16920975, PMID:19525930, PMID:23702389], and on CD4+ cells and microglia it acts as an HIV-1 co-receptor whose usage depends on the gp120 V3 region [PMID:8674119, PMID:8674120, PMID:9024664]. Genetic eotaxin/CCR3 epistasis in mouse asthma models establishes its non-redundant requirement for allergen- and IL-13-driven airway eosinophilia and remodeling [PMID:16210640, PMID:17148674].","teleology":[{"year":1996,"claim":"Established that CCR3 has a function beyond chemokine signaling by acting as an HIV-1 entry co-receptor, defining a host-pathogen role for the receptor.","evidence":"CCR3/CD4 co-expression infectivity assay with eotaxin competition and V3-dependent isolate mapping","pmids":["8674119","8674120"],"confidence":"High","gaps":["Restricted to a subset of HIV-1 isolates","Physiological relevance relative to CCR5 in vivo not resolved"]},{"year":1997,"claim":"Defined CCR3 co-receptor function in primary CNS cells, extending HIV-1 entry relevance to microglia.","evidence":"Primary microglial infection with anti-CCR3 antibody and eotaxin blocking","pmids":["9024664"],"confidence":"High","gaps":["Relative contribution of CCR3 versus CCR5 in CNS infection unquantified"]},{"year":1997,"claim":"Showed CCR3 is selectively expressed on Th2 cells and functionally couples eotaxin to calcium flux and chemotaxis, linking the receptor to the Th2 axis of allergic immunity.","evidence":"Antibody-based Th2 isolation, Ca2+ measurement, and chemotaxis assays","pmids":["9302298","9480044"],"confidence":"High","gaps":["Transcriptional control of Th2-selective expression not addressed"]},{"year":1999,"claim":"Determined that eosinophil degranulation is mediated exclusively through CCR3, separating effector (granule release) from generic calcium signaling and establishing CCR3 as the key eosinophil effector receptor.","evidence":"Ca2+ flux, eosinophil-derived neurotoxin RIA, and antibody blocking on purified eosinophils with multiple ligands","pmids":["10984371"],"confidence":"High","gaps":["Signaling steps coupling CCR3 to granule exocytosis not defined here"]},{"year":2000,"claim":"Mapped the eotaxin-binding surface to the CCR3 N-terminal region, providing the first structural basis for ligand recognition.","evidence":"Synthetic peptide binding screens and NMR characterization of the eotaxin–CCR3 N-terminus interface","pmids":["10859315"],"confidence":"High","gaps":["Does not address transmembrane activation determinants","Post-translational modification of the N-terminus not yet defined"]},{"year":2000,"claim":"Extended functional CCR3 expression to platelets, broadening its role beyond leukocyte chemotaxis to hemostatic activation.","evidence":"RT-PCR, flow cytometry, Ca2+, aggregation/granule release assays with glycosaminoglycan cleavage","pmids":["11110672"],"confidence":"Medium","gaps":["In vivo platelet relevance not established","Single lab"]},{"year":2001,"claim":"Demonstrated functional CCR3 on airway epithelium coupling eotaxin to pertussis-toxin-sensitive Gi signaling and tyrosine phosphorylation, implicating non-hematopoietic cells in CCR3 biology.","evidence":"Northern/Western blot, Ca2+ flux, tyrosine phosphorylation, radioligand binding, pertussis toxin and antibody blocking","pmids":["11160184"],"confidence":"High","gaps":["Downstream transcriptional outputs not fully mapped here"]},{"year":2003,"claim":"Revealed cross-regulation between chemokine systems by showing CXCR3 ligands antagonize CCR3 and that CCL11/CXCL11 share overlapping CCR3 extracellular binding sites.","evidence":"Ca2+ flux, chemotaxis, CCR3-CCR1 chimeric receptors, and radioligand binding","pmids":["12884299"],"confidence":"High","gaps":["Physiological significance of cross-receptor antagonism in vivo unclear"]},{"year":2005,"claim":"Established the non-redundant, hierarchical requirement of CCR3 and its eotaxin ligands for allergen-induced airway eosinophilia using genetic epistasis.","evidence":"Eotaxin-1/2 and CCR3 knockout combinations in an OVA asthma model with BAL and tissue eosinophil counts","pmids":["16210640"],"confidence":"High","gaps":["Tissue-compartment-specific ligand contributions only partly resolved"]},{"year":2005,"claim":"Linked CCR3-driven eosinophil recruitment to airway nerves and M2 muscarinic dysfunction, connecting the receptor to airway hyperresponsiveness mechanistically.","evidence":"Guinea pig antigen challenge with CCR3 antagonist, vagal/M2R functional assays, and cytokine-stimulated neuron culture","pmids":["16374515"],"confidence":"High","gaps":["Molecular signal for nerve-directed eosinophil clustering not defined"]},{"year":2006,"claim":"Showed CCR3 is required for IL-13-driven airway remodeling, extending its role from cell recruitment to structural tissue changes.","evidence":"IL-13 transgenic × CCR3-deficient crosses with histology and ΔdblGATA eosinophil-deficient controls","pmids":["17148674"],"confidence":"High","gaps":["Whether remodeling is fully eosinophil-dependent versus direct CCR3 action unresolved"]},{"year":2007,"claim":"Identified the transmembrane residues (Tyr-41, Tyr-113, Glu-287) shared by agonists and antagonists, defining the small-molecule pharmacophore and an agonist/antagonist switch at Y113.","evidence":"Site-directed mutagenesis, CCR3-CCR1 chimeras, chemotaxis and Ca2+ assays","pmids":["17635911"],"confidence":"High","gaps":["No high-resolution ligand-bound structure at the time"]},{"year":2009,"claim":"Uncovered an eosinophil-independent CCR3 role on choroidal neovascular endothelium, repositioning the receptor as a target in age-related macular degeneration.","evidence":"Human AMD immunohistochemistry, mouse CNV genetic/pharmacological targeting, endothelial proliferation assays, cell-type-deficient mouse controls","pmids":["19525930"],"confidence":"High","gaps":["Endothelial CCR3 signaling pathway in angiogenesis not detailed"]},{"year":2013,"claim":"Defined the Gαi→PI3K/ERK/p38 signaling and integrin-dependent spreading required for CCR3-driven eosinophil RNase secretion, mapping the effector signaling cascade.","evidence":"RNase activity assays in mouse and human eosinophils with pathway inhibitors and integrin-blocking antibodies","pmids":["23742707"],"confidence":"Medium","gaps":["Single lab","Spatial coordination of integrin and CCR3 signaling not resolved"]},{"year":2014,"claim":"Established that tyrosine sulfation of the CCR3 N-terminus is a critical determinant of high-affinity eotaxin binding, defining a post-translational regulatory layer of ligand recognition.","evidence":"NMR structure of CCL11 bound to sulfo-CCR3(8-23) with functional sulfation validation","pmids":["25450766"],"confidence":"High","gaps":["Regulation of CCR3 sulfation in vivo not addressed"]},{"year":2018,"claim":"Demonstrated biased antagonism of CCR3, showing a peptide nanoparticle can selectively inhibit early ERK signaling while promoting receptor internalization, refining therapeutic targeting concepts.","evidence":"NMR binding, time-resolved ERK Western blot, confocal internalization, and in vivo allergen asthma model","pmids":["29778505"],"confidence":"High","gaps":["β-arrestin-associated late signaling consequences in disease not fully mapped"]},{"year":2021,"claim":"Identified cholesterol as a positive allosteric modulator coupling membrane lipid environment to CCR3 ligand affinity and Gαi3 GTPase output.","evidence":"Reconstituted recombinant CCR3 in SMALPs/proteoliposomes with affinity and Gαi3 GTPase assays","pmids":["34490352"],"confidence":"Medium","gaps":["In vitro reconstitution only","Cellular cholesterol modulation of CCR3 not tested"]},{"year":2022,"claim":"Provided a cryo-EM structure establishing ICL2 as the principal determinant of CCR3 G-protein coupling, defining the activation architecture.","evidence":"Apo-state cryo-EM structure with functional mutagenesis","pmids":["35570218"],"confidence":"High","gaps":["No ligand- or G-protein-bound active-state structure reported here"]},{"year":null,"claim":"How CCR3's broad non-eosinophil functions (endothelial angiogenesis, fibroblast/cardiac fibrosis, tumor invasion, neuronal hyperexcitability, age-related cognitive decline) are encoded by distinct ligand-, cell-type-, or biased-signaling programs remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Cell-type-specific downstream signaling not unified","Whether distinct ligands (CCL7, CCL8, CCL24, CCL26) bias different outcomes is unclear","Active-state structures with diverse ligands lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[2,5,10,21]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[31]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,10,21,32]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[24,31,32]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,5,16]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,1,22]}],"complexes":[],"partners":["CCL11","CCL24","CCL26","CCL7","CCL8","GNAI3","CD4","EGFR"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P51677","full_name":"C-C chemokine receptor type 3","aliases":["Eosinophil eotaxin receptor"],"length_aa":355,"mass_kda":41.0,"function":"G protein-coupled receptor (GPCR) that plays a key role in the immune system by regulating the migration and activation of white blood cells in response to chemokines (PubMed:28994588). Selectively interacts with eosinophil-attracting chemokines such as eotaxin/CCL11, eotaxin-2/CCL24 and eotaxin-3/CCL26 (PubMed:7622448, PubMed:8642344, PubMed:8676064). Ligand binding triggers intracellular signaling that leads to chemotaxis of immune cells. Mechanistically, signals through GNA14 or GNA16 to induce stimulation of phospholipase Cbeta/PLCB2 and subsequently chemotaxis (PubMed:18406577). Alternatively, transduces signal via GNAI1 resulting in elevated intracellular calcium levels and activation of the PI3K/AKT pathway (PubMed:8676064, PubMed:35570218). May also act as a possible functional receptor for NARS1 (PubMed:30171954) (Microbial infection) Alternative coreceptor with CD4 for HIV-1 infection","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P51677/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CCR3","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CCR3","total_profiled":1310},"omim":[{"mim_id":"612007","title":"CELIAC DISEASE, SUSCEPTIBILITY TO, 9; CELIAC9","url":"https://www.omim.org/entry/612007"},{"mim_id":"612006","title":"CELIAC DISEASE, SUSCEPTIBILITY TO, 8; CELIAC8","url":"https://www.omim.org/entry/612006"},{"mim_id":"610247","title":"ESOPHAGITIS, EOSINOPHILIC, 1; EOE1","url":"https://www.omim.org/entry/610247"},{"mim_id":"604836","title":"CHEMOKINE, CC MOTIF, RECEPTOR 4; CCR4","url":"https://www.omim.org/entry/604836"},{"mim_id":"604697","title":"CHEMOKINE, CC MOTIF, LIGAND 26; CCL26","url":"https://www.omim.org/entry/604697"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":2.4},{"tissue":"lymphoid tissue","ntpm":1.5},{"tissue":"skeletal muscle","ntpm":1.6}],"url":"https://www.proteinatlas.org/search/CCR3"},"hgnc":{"alias_symbol":["CC-CKR-3","CKR3","CD193"],"prev_symbol":["CMKBR3"]},"alphafold":{"accession":"P51677","domains":[{"cath_id":"1.20.1070.10","chopping":"26-312","consensus_level":"medium","plddt":92.1038,"start":26,"end":312}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P51677","model_url":"https://alphafold.ebi.ac.uk/files/AF-P51677-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P51677-F1-predicted_aligned_error_v6.png","plddt_mean":83.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CCR3","jax_strain_url":"https://www.jax.org/strain/search?query=CCR3"},"sequence":{"accession":"P51677","fasta_url":"https://rest.uniprot.org/uniprotkb/P51677.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P51677/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P51677"}},"corpus_meta":[{"pmid":"8674119","id":"PMC_8674119","title":"The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.","date":"1996","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8674119","citation_count":2054,"is_preprint":false},{"pmid":"8674120","id":"PMC_8674120","title":"A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.","date":"1996","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8674120","citation_count":1669,"is_preprint":false},{"pmid":"9302298","id":"PMC_9302298","title":"Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells.","date":"1997","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9302298","citation_count":818,"is_preprint":false},{"pmid":"9024664","id":"PMC_9024664","title":"CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia.","date":"1997","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9024664","citation_count":778,"is_preprint":false},{"pmid":"10432289","id":"PMC_10432289","title":"T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro.","date":"1999","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10432289","citation_count":267,"is_preprint":false},{"pmid":"9480044","id":"PMC_9480044","title":"Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils.","date":"1997","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/9480044","citation_count":218,"is_preprint":false},{"pmid":"11056090","id":"PMC_11056090","title":"Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation.","date":"2000","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/11056090","citation_count":206,"is_preprint":false},{"pmid":"19525930","id":"PMC_19525930","title":"CCR3 is a target for age-related macular degeneration diagnosis and therapy.","date":"2009","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/19525930","citation_count":202,"is_preprint":false},{"pmid":"11110672","id":"PMC_11110672","title":"Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11110672","citation_count":201,"is_preprint":false},{"pmid":"16210640","id":"PMC_16210640","title":"The eotaxin chemokines and CCR3 are fundamental regulators of allergen-induced pulmonary eosinophilia.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16210640","citation_count":190,"is_preprint":false},{"pmid":"9886422","id":"PMC_9886422","title":"Up-regulation of CCR1 and CCR3 and induction of chemotaxis to CC chemokines by IFN-gamma in human neutrophils.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9886422","citation_count":168,"is_preprint":false},{"pmid":"10900353","id":"PMC_10900353","title":"Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue.","date":"2000","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/10900353","citation_count":162,"is_preprint":false},{"pmid":"10417617","id":"PMC_10417617","title":"Enhanced expression of eotaxin and CCR3 in atopic dermatitis.","date":"1999","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/10417617","citation_count":154,"is_preprint":false},{"pmid":"10072545","id":"PMC_10072545","title":"Differential regulation of eosinophil chemokine signaling via CCR3 and non-CCR3 pathways.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10072545","citation_count":152,"is_preprint":false},{"pmid":"11704586","id":"PMC_11704586","title":"Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma.","date":"2001","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11704586","citation_count":111,"is_preprint":false},{"pmid":"16374515","id":"PMC_16374515","title":"Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction.","date":"2005","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/16374515","citation_count":110,"is_preprint":false},{"pmid":"12884299","id":"PMC_12884299","title":"CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11.","date":"2003","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12884299","citation_count":108,"is_preprint":false},{"pmid":"10984371","id":"PMC_10984371","title":"Chemokines induce eosinophil degranulation through CCR-3.","date":"2000","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10984371","citation_count":108,"is_preprint":false},{"pmid":"16314464","id":"PMC_16314464","title":"Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis.","date":"2005","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16314464","citation_count":97,"is_preprint":false},{"pmid":"11160184","id":"PMC_11160184","title":"Expression of the C-C chemokine receptor CCR3 in human airway epithelial cells.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11160184","citation_count":96,"is_preprint":false},{"pmid":"9394815","id":"PMC_9394815","title":"The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3.","date":"1997","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9394815","citation_count":91,"is_preprint":false},{"pmid":"15814620","id":"PMC_15814620","title":"Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma.","date":"2005","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/15814620","citation_count":90,"is_preprint":false},{"pmid":"27167205","id":"PMC_27167205","title":"Crosstalk between CCL7 and CCR3 promotes metastasis of colon cancer cells via ERK-JNK signaling pathways.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27167205","citation_count":90,"is_preprint":false},{"pmid":"12496441","id":"PMC_12496441","title":"The CCR3 receptor is involved in eosinophil differentiation and is up-regulated by Th2 cytokines in CD34+ progenitor cells.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12496441","citation_count":83,"is_preprint":false},{"pmid":"24286456","id":"PMC_24286456","title":"Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial.","date":"2014","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24286456","citation_count":79,"is_preprint":false},{"pmid":"20505746","id":"PMC_20505746","title":"Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma.","date":"2010","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/20505746","citation_count":77,"is_preprint":false},{"pmid":"35570218","id":"PMC_35570218","title":"Molecular insights into ligand recognition and activation of chemokine receptors CCR2 and CCR3.","date":"2022","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35570218","citation_count":76,"is_preprint":false},{"pmid":"17148674","id":"PMC_17148674","title":"Eosinophils and CCR3 regulate interleukin-13 transgene-induced pulmonary remodeling.","date":"2006","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17148674","citation_count":76,"is_preprint":false},{"pmid":"14561178","id":"PMC_14561178","title":"Eotaxins and CCR3 receptor in inflammatory and allergic skin diseases: therapeutical implications.","date":"2003","source":"Current drug targets. Inflammation and allergy","url":"https://pubmed.ncbi.nlm.nih.gov/14561178","citation_count":74,"is_preprint":false},{"pmid":"15130922","id":"PMC_15130922","title":"CCL11 (Eotaxin) induces CCR3-dependent smooth muscle cell migration.","date":"2004","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15130922","citation_count":74,"is_preprint":false},{"pmid":"15673545","id":"PMC_15673545","title":"Differential expression of CCR3 and CXCR3 by human lung and bone marrow-derived mast cells: implications for tissue mast cell migration.","date":"2005","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/15673545","citation_count":74,"is_preprint":false},{"pmid":"16081847","id":"PMC_16081847","title":"CCR3 expression and function in asthmatic airway smooth muscle cells.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16081847","citation_count":72,"is_preprint":false},{"pmid":"10859315","id":"PMC_10859315","title":"Characterization of binding between the chemokine eotaxin and peptides derived from the chemokine receptor CCR3.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10859315","citation_count":70,"is_preprint":false},{"pmid":"12393570","id":"PMC_12393570","title":"Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12393570","citation_count":69,"is_preprint":false},{"pmid":"9864143","id":"PMC_9864143","title":"CC chemokine receptors, CCR-1 and CCR-3, are potentially involved in antigen-presenting cell function of human peripheral blood monocyte-derived dendritic cells.","date":"1999","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9864143","citation_count":66,"is_preprint":false},{"pmid":"25450766","id":"PMC_25450766","title":"Structural basis of receptor sulfotyrosine recognition by a CC chemokine: the N-terminal region of CCR3 bound to CCL11/eotaxin-1.","date":"2014","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/25450766","citation_count":66,"is_preprint":false},{"pmid":"10642580","id":"PMC_10642580","title":"Expression of the chemokine eotaxin and its receptor, CCR3, in human endometrium.","date":"2000","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/10642580","citation_count":65,"is_preprint":false},{"pmid":"24604010","id":"PMC_24604010","title":"Eotaxin-1 promotes prostate cancer cell invasion via activation of the CCR3-ERK pathway and upregulation of MMP-3 expression.","date":"2014","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24604010","citation_count":65,"is_preprint":false},{"pmid":"19223978","id":"PMC_19223978","title":"High-level production, solubilization and purification of synthetic human GPCR chemokine receptors CCR5, CCR3, CXCR4 and CX3CR1.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19223978","citation_count":64,"is_preprint":false},{"pmid":"11306952","id":"PMC_11306952","title":"Expression of the chemokine receptor CCR3 on human mast cells.","date":"2001","source":"International archives of allergy and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11306952","citation_count":59,"is_preprint":false},{"pmid":"29778505","id":"PMC_29778505","title":"Novel peptide nanoparticle-biased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness.","date":"2018","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29778505","citation_count":59,"is_preprint":false},{"pmid":"9687538","id":"PMC_9687538","title":"HIV-specific T cell cytotoxicity mediated by RANTES via the chemokine receptor CCR3.","date":"1998","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9687538","citation_count":55,"is_preprint":false},{"pmid":"24641500","id":"PMC_24641500","title":"Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4.","date":"2014","source":"Expert opinion on drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/24641500","citation_count":54,"is_preprint":false},{"pmid":"17635911","id":"PMC_17635911","title":"Small molecule receptor agonists and antagonists of CCR3 provide insight into mechanisms of chemokine receptor activation.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17635911","citation_count":53,"is_preprint":false},{"pmid":"12218106","id":"PMC_12218106","title":"Expression of a functional eotaxin (CC chemokine ligand 11) receptor CCR3 by human dendritic cells.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12218106","citation_count":52,"is_preprint":false},{"pmid":"19967721","id":"PMC_19967721","title":"Small molecule antagonists for chemokine CCR3 receptors.","date":"2010","source":"Medicinal research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19967721","citation_count":49,"is_preprint":false},{"pmid":"9353270","id":"PMC_9353270","title":"Chemokine receptor CCR3 function is highly dependent on local pH and ionic strength.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9353270","citation_count":49,"is_preprint":false},{"pmid":"14561201","id":"PMC_14561201","title":"Eotaxin receptor (CCR3) antagonism in asthma and allergic disease.","date":"2002","source":"Current drug targets. Inflammation and allergy","url":"https://pubmed.ncbi.nlm.nih.gov/14561201","citation_count":48,"is_preprint":false},{"pmid":"15662971","id":"PMC_15662971","title":"Up-regulation of CC chemokine, CCL3L1, and receptors, CCR3, CCR5 in human glioblastoma that promotes cell growth.","date":"2004","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15662971","citation_count":48,"is_preprint":false},{"pmid":"11238088","id":"PMC_11238088","title":"CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the nonneoplastic leukocytic infiltrates of Hodgkin disease.","date":"2001","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11238088","citation_count":47,"is_preprint":false},{"pmid":"21077277","id":"PMC_21077277","title":"Increased expression of chemokine receptor CCR3 and its ligands in ulcerative colitis: the role of colonic epithelial cells in in vitro studies.","date":"2010","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21077277","citation_count":46,"is_preprint":false},{"pmid":"23702389","id":"PMC_23702389","title":"The chemokine receptor CCR3 participates in tissue remodeling during atopic skin inflammation.","date":"2013","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/23702389","citation_count":46,"is_preprint":false},{"pmid":"11060659","id":"PMC_11060659","title":"CCR3 blockade as a new therapy for asthma.","date":"2000","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/11060659","citation_count":45,"is_preprint":false},{"pmid":"15771462","id":"PMC_15771462","title":"Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.","date":"2005","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15771462","citation_count":44,"is_preprint":false},{"pmid":"19490431","id":"PMC_19490431","title":"CCR3, CCR2A and macrophage inflammatory protein (MIP)-1a, monocyte chemotactic protein-1 (MCP-1) in the mouse hippocampus during and after pilocarpine-induced status epilepticus (PISE) .","date":"2009","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/19490431","citation_count":44,"is_preprint":false},{"pmid":"16920975","id":"PMC_16920975","title":"Functional analysis of the chemokine receptor CCR3 on airway epithelial cells.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16920975","citation_count":43,"is_preprint":false},{"pmid":"21406396","id":"PMC_21406396","title":"CCL11-CCR3 interactions promote survival of anaplastic large cell lymphoma cells via ERK1/2 activation.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21406396","citation_count":43,"is_preprint":false},{"pmid":"11991282","id":"PMC_11991282","title":"Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis.","date":"2002","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/11991282","citation_count":42,"is_preprint":false},{"pmid":"11544337","id":"PMC_11544337","title":"IL-3 induces down-regulation of CCR3 protein and mRNA in human eosinophils.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11544337","citation_count":41,"is_preprint":false},{"pmid":"11809592","id":"PMC_11809592","title":"Increased expression of eotaxin and its specific receptor CCR3 in bullous pemphigoid.","date":"2002","source":"European journal of dermatology : EJD","url":"https://pubmed.ncbi.nlm.nih.gov/11809592","citation_count":41,"is_preprint":false},{"pmid":"25986216","id":"PMC_25986216","title":"A polymorphism in CCR1/CCR3 is associated with narcolepsy.","date":"2015","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/25986216","citation_count":40,"is_preprint":false},{"pmid":"21945903","id":"PMC_21945903","title":"CCR3 Blockade Attenuates Eosinophilic Ileitis and Associated Remodeling.","date":"2011","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21945903","citation_count":40,"is_preprint":false},{"pmid":"15948978","id":"PMC_15948978","title":"Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis.","date":"2005","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/15948978","citation_count":38,"is_preprint":false},{"pmid":"35354939","id":"PMC_35354939","title":"Gene knockdown of CCR3 reduces eosinophilic inflammation and the Th2 immune response by inhibiting the PI3K/AKT pathway in allergic rhinitis mice.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35354939","citation_count":37,"is_preprint":false},{"pmid":"11202173","id":"PMC_11202173","title":"Expression pattern of CXCR3, CXCR4, and CCR3 chemokine receptors in the developing human brain.","date":"2001","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/11202173","citation_count":37,"is_preprint":false},{"pmid":"32051393","id":"PMC_32051393","title":"Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32051393","citation_count":36,"is_preprint":false},{"pmid":"23742707","id":"PMC_23742707","title":"PI3K, ERK, p38 MAPK and integrins regulate CCR3-mediated secretion of mouse and human eosinophil-associated RNases.","date":"2013","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/23742707","citation_count":34,"is_preprint":false},{"pmid":"29281969","id":"PMC_29281969","title":"Functional expression of CCL8 and its interaction with chemokine receptor CCR3.","date":"2017","source":"BMC immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29281969","citation_count":32,"is_preprint":false},{"pmid":"21358803","id":"PMC_21358803","title":"CCR3 and choroidal neovascularization.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21358803","citation_count":32,"is_preprint":false},{"pmid":"24917456","id":"PMC_24917456","title":"A role for CCL28-CCR3 in T-cell homing to the human upper airway mucosa.","date":"2014","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24917456","citation_count":31,"is_preprint":false},{"pmid":"21660963","id":"PMC_21660963","title":"Pulmonary epithelial CCR3 promotes LPS-induced lung inflammation by mediating release of IL-8.","date":"2011","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21660963","citation_count":31,"is_preprint":false},{"pmid":"23404125","id":"PMC_23404125","title":"Suppression of laser-induced choroidal neovascularization by a CCR3 antagonist.","date":"2013","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/23404125","citation_count":30,"is_preprint":false},{"pmid":"36131165","id":"PMC_36131165","title":"CCL24/CCR3 axis plays a central role in angiotensin II-induced heart failure by stimulating M2 macrophage polarization and fibroblast activation.","date":"2022","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/36131165","citation_count":30,"is_preprint":false},{"pmid":"16449815","id":"PMC_16449815","title":"Increased expression of RANTES, CCR3 and CCR5 in the lesional skin of patients with atopic eczema.","date":"2006","source":"International archives of allergy and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16449815","citation_count":29,"is_preprint":false},{"pmid":"26409848","id":"PMC_26409848","title":"Upregulated expression of CCR3 in osteoarthritis and CCR3 mediated activation of fibroblast-like synoviocytes.","date":"2015","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/26409848","citation_count":28,"is_preprint":false},{"pmid":"16343433","id":"PMC_16343433","title":"In vitro and in vivo characterization of a novel CCR3 antagonist, YM-344031.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16343433","citation_count":27,"is_preprint":false},{"pmid":"17983872","id":"PMC_17983872","title":"Genetic effect of CCR3 and IL5RA gene polymorphisms on eosinophilia in asthmatic patients.","date":"2007","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17983872","citation_count":26,"is_preprint":false},{"pmid":"26188133","id":"PMC_26188133","title":"Novel CCR3 Antagonists Are Effective Mono- and Combination Inhibitors of Choroidal Neovascular Growth and Vascular Permeability.","date":"2015","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26188133","citation_count":26,"is_preprint":false},{"pmid":"15219825","id":"PMC_15219825","title":"Activation of epidermal growth factor receptor via CCR3 in bronchial epithelial cells.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15219825","citation_count":23,"is_preprint":false},{"pmid":"28458639","id":"PMC_28458639","title":"CCR3 Is Associated with the Death of a Photoreceptor Cell-line Induced by Light Exposure.","date":"2017","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28458639","citation_count":22,"is_preprint":false},{"pmid":"34490352","id":"PMC_34490352","title":"Cholesterol Is a Dose-Dependent Positive Allosteric Modulator of CCR3 Ligand Affinity and G Protein Coupling.","date":"2021","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/34490352","citation_count":22,"is_preprint":false},{"pmid":"31151084","id":"PMC_31151084","title":"CCL26 and CCR3 are associated with the acute inflammatory response in the CNS in experimental autoimmune encephalomyelitis.","date":"2019","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/31151084","citation_count":22,"is_preprint":false},{"pmid":"37922997","id":"PMC_37922997","title":"IgE directly affects eosinophil migration in chronic rhinosinusitis with nasal polyps through CCR3 and predicts the efficacy of omalizumab.","date":"2023","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37922997","citation_count":21,"is_preprint":false},{"pmid":"35887133","id":"PMC_35887133","title":"Potent CCR3 Receptor Antagonist, SB328437, Suppresses Colonic Eosinophil Chemotaxis and Inflammation in the Winnie Murine Model of Spontaneous Chronic Colitis.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35887133","citation_count":21,"is_preprint":false},{"pmid":"12902471","id":"PMC_12902471","title":"CCR3 expression induced by IL-2 and IL-4 functioning as a death receptor for B cells.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12902471","citation_count":21,"is_preprint":false},{"pmid":"11069055","id":"PMC_11069055","title":"The CC chemokine receptor 3 CCR3 is functionally expressed on eosinophils but not on neutrophils.","date":"2000","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11069055","citation_count":21,"is_preprint":false},{"pmid":"10708591","id":"PMC_10708591","title":"Cell-type-dependent induction of eotaxin and CCR3 by ionizing radiation.","date":"2000","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10708591","citation_count":21,"is_preprint":false},{"pmid":"16461999","id":"PMC_16461999","title":"A specific CCR3 chemokine receptor antagonist inhibits both early and late phase allergic inflammation in the conjunctiva.","date":"2005","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/16461999","citation_count":21,"is_preprint":false},{"pmid":"14561176","id":"PMC_14561176","title":"CCR3 and CXCR3 as drug targets for allergy: principles and potential.","date":"2003","source":"Current drug targets. Inflammation and allergy","url":"https://pubmed.ncbi.nlm.nih.gov/14561176","citation_count":20,"is_preprint":false},{"pmid":"11196669","id":"PMC_11196669","title":"New variations of human CC-chemokine receptors CCR3 and CCR4.","date":"1999","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11196669","citation_count":20,"is_preprint":false},{"pmid":"33608009","id":"PMC_33608009","title":"Asthma-related inflammation promotes lung metastasis of breast cancer cells through CCL11-CCR3 pathway.","date":"2021","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/33608009","citation_count":20,"is_preprint":false},{"pmid":"10733106","id":"PMC_10733106","title":"Receptor reserve analysis of the human CCR3 receptor in eosinophils and CCR3-transfected cells.","date":"2000","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/10733106","citation_count":20,"is_preprint":false},{"pmid":"18954648","id":"PMC_18954648","title":"CCR3- and CXCR4-mediated interactions regulate migration of CD34+ human bone marrow progenitors to ischemic myocardium and subsequent tissue repair.","date":"2008","source":"The Journal of thoracic and cardiovascular surgery","url":"https://pubmed.ncbi.nlm.nih.gov/18954648","citation_count":20,"is_preprint":false},{"pmid":"36998150","id":"PMC_36998150","title":"Chemokine CCL7 mediates trigeminal neuropathic pain via CCR2/CCR3-ERK pathway in the trigeminal ganglion of mice.","date":"2023","source":"Molecular pain","url":"https://pubmed.ncbi.nlm.nih.gov/36998150","citation_count":19,"is_preprint":false},{"pmid":"21844117","id":"PMC_21844117","title":"Enhanced CCR5+/CCR3+ T helper cell ratio in patients with active cutaneous lupus erythematosus.","date":"2011","source":"Lupus","url":"https://pubmed.ncbi.nlm.nih.gov/21844117","citation_count":19,"is_preprint":false},{"pmid":"36934154","id":"PMC_36934154","title":"CCR3 plays a role in murine age-related cognitive changes and T-cell infiltration into the brain.","date":"2023","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/36934154","citation_count":18,"is_preprint":false},{"pmid":"29968270","id":"PMC_29968270","title":"Targeting eotaxin-1 and CCR3 receptor alleviates enteric neuropathy and colonic dysfunction in TNBS-induced colitis in guinea pigs.","date":"2018","source":"Neurogastroenterology and motility","url":"https://pubmed.ncbi.nlm.nih.gov/29968270","citation_count":18,"is_preprint":false},{"pmid":"16919271","id":"PMC_16919271","title":"Apolipoprotein E deficiency increased microglial activation/CCR3 expression and hippocampal damage in kainic acid exposed mice.","date":"2006","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16919271","citation_count":18,"is_preprint":false},{"pmid":"20050333","id":"PMC_20050333","title":"The function of CCR3 on mouse bone marrow-derived mast cells in vitro.","date":"2010","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20050333","citation_count":17,"is_preprint":false},{"pmid":"37421620","id":"PMC_37421620","title":"Rebalancing liver-infiltrating CCR3+ and CD206+ monocytes improves diet-induced NAFLD.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37421620","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53883,"output_tokens":9283,"usd":0.150447,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19497,"output_tokens":4966,"usd":0.110817,"stage2_stop_reason":"end_turn"},"total_usd":0.261264,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"CCR3, when co-expressed with CD4 on otherwise non-permissive cells, functions as a co-receptor for entry by a restricted subset of primary HIV-1 isolates; binding of the CCR3 ligand eotaxin inhibits HIV-1 infection, and co-receptor usage depends on the V3 region of gp120.\",\n      \"method\": \"Cell-based infectivity assay with CCR3-transfected cell lines co-expressing CD4; ligand competition experiment\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — functional reconstitution in transfected cells, ligand competition, replicated independently in the same issue (PMID:8674120)\",\n      \"pmids\": [\"8674119\", \"8674120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CCR3 and CCR5 are both expressed on brain microglia and serve as co-receptors for HIV-1 infection of these CNS cells; the CCR3 ligand eotaxin and anti-CCR3 antibody inhibited HIV-1 infection of microglia.\",\n      \"method\": \"Primary microglial infection assay; antibody/ligand blocking experiments\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct infection assay with blocking antibody and ligand competition in primary CNS cells, replicated across multiple papers\",\n      \"pmids\": [\"9024664\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CCR3 is selectively expressed on human Th2 (but not Th1) cells; eotaxin stimulation of CCR3+ T cells induces intracellular calcium increase and chemotaxis.\",\n      \"method\": \"Anti-CCR3 antibody-based cell isolation; intracellular calcium measurement; chemotaxis assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (antibody isolation, Ca2+ flux, chemotaxis), replicated in independent lab (PMID:9480044)\",\n      \"pmids\": [\"9302298\", \"9480044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CCR3 function (eotaxin binding and CCR3-mediated calcium mobilization and eosinophil chemotaxis) is markedly sensitive to small changes in extracellular pH and ionic strength (NaCl concentration) within physiological and near-physiological ranges.\",\n      \"method\": \"Radioligand binding assay; Ca2+ mobilization assay; in vitro eosinophil chemotaxis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays in a single lab demonstrating pH/ionic-strength sensitivity\",\n      \"pmids\": [\"9353270\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"IFN-γ treatment of human neutrophils induces CCR3 (and CCR1) mRNA and surface expression, enabling functional chemotactic responses to eotaxin; an anti-CCR3 monoclonal antibody (7B11) blocked this eotaxin-induced chemotaxis.\",\n      \"method\": \"RT-PCR; radioligand binding; in vitro chemotaxis assay with blocking mAb\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (mRNA, binding, chemotaxis + antibody block), single lab\",\n      \"pmids\": [\"9886422\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Chemokine-induced eosinophil degranulation (eosinophil-derived neurotoxin release) is mediated exclusively through CCR3; non-CCR3 ligands that induce calcium influx do not induce degranulation, and anti-CCR3 antibody significantly inhibited CCR3-ligand-induced degranulation.\",\n      \"method\": \"Ca2+ flux assay; RIA for eosinophil-derived neurotoxin; antibody blocking experiments on purified eosinophils\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal assays (Ca2+ flux, degranulation, blocking antibody) in purified primary cells, specificity rigorously tested with multiple ligands\",\n      \"pmids\": [\"10984371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Met-RANTES acts as an antagonist of human eosinophil effector functions (Ca2+ transients, actin polymerization, reactive oxygen species release) through CCR1 preferentially over CCR3; eotaxin-induced responses via CCR3 were only partially blocked at concentrations that fully blocked RANTES/MCP-3 responses.\",\n      \"method\": \"Ca2+ flux assay; actin polymerization assay; reactive oxygen species assay; dose-response antagonism with Met-RANTES on purified eosinophils\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple effector function assays with a pharmacological antagonist, single lab\",\n      \"pmids\": [\"9394815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The N-terminal region of CCR3 (residues 1–35, especially the DDYY-containing central region around residues 8–23) is the primary binding surface for eotaxin; the N-loop, 3(10)-helical turn, and β2-β3 hairpin of eotaxin form the complementary receptor-binding groove.\",\n      \"method\": \"Synthetic peptide binding screens; NMR spectroscopy (1H-15N HSQC, 2D/3D homonuclear NMR, 15N-filtered TOCSY); dissociation constant measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structural characterization with peptide binding affinities, single lab but rigorous structural approach\",\n      \"pmids\": [\"10859315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CCR3 is functionally expressed on human platelets; eotaxin activates platelets via CCR3, inducing Ca2+ signals, aggregation, and granule release; these responses are partially dependent on secondary ADP release and are inhibited by cleavage of heparan/chondroitin sulfate on the platelet surface.\",\n      \"method\": \"RT-PCR; flow cytometry; immunoprecipitation/Western blot; Ca2+ measurement; aggregation and granule release assays; glycosaminoglycan cleavage experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods confirming functional CCR3 on platelets, single lab\",\n      \"pmids\": [\"11110672\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CCL11 (eotaxin) induces CCR3-dependent smooth muscle cell (SMC) chemotaxis and migration; anti-CCR3 antibody (but not anti-CCR2) blocked SMC migration; CCR3 is upregulated in medial SMCs after arterial injury in a pattern consistent with a migratory phenotype.\",\n      \"method\": \"RT-PCR; Western blot; flow cytometry; Boyden chamber chemotaxis assay; scrape-wound assay; antibody blocking; in vivo mouse femoral artery injury model with immunostaining\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal in vitro assays plus in vivo validation, antibody specificity controls\",\n      \"pmids\": [\"15130922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCR3 is functionally expressed on airway epithelial cells; eotaxin stimulates intracellular Ca2+ flux and tyrosine phosphorylation of cellular proteins via epithelial CCR3; these signals are blocked by anti-CCR3 mAb (7B11) or pertussis toxin, and 125I-eotaxin binding confirms expected ligand specificity.\",\n      \"method\": \"Northern blot; Western blot; flow cytometry; Ca2+ flux assay; tyrosine phosphorylation assay; radioligand binding; pertussis toxin treatment; antibody blocking\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (mRNA, protein, Ca2+ signaling, phosphorylation, radioligand binding, pharmacological/antibody blocking) in primary and cell-line models\",\n      \"pmids\": [\"11160184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"IL-3 induces dose- and time-dependent down-regulation of CCR3 surface expression and mRNA in human eosinophils; this down-regulation is prevented by anti-IL-3 antibody and by phenylarsine oxide (an inhibitor of receptor internalization), and is partially inhibited by the PI3K inhibitor wortmannin, indicating a distinct internalization mechanism from eotaxin-induced down-regulation.\",\n      \"method\": \"Flow cytometry; RT-PCR; Ca2+ flux assay; pharmacological inhibition (wortmannin, phenylarsine oxide); blocking antibody\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple assays (flow cytometry, mRNA, pharmacological inhibitors) in primary eosinophils, single lab\",\n      \"pmids\": [\"11544337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Eotaxin induces differentiation of eosinophils from CD34+ cord blood progenitor cells via CCR3 (which is expressed and functional on these progenitors); this differentiation is IL-3-, IL-5-, and GM-CSF-independent, and Th2 cytokines up-regulate CCR3 surface expression on progenitors while IL-12/IFN-γ decreases it.\",\n      \"method\": \"In situ RT-PCR; immunostaining; flow cytometry; Ca2+ mobilization assay; in vitro eosinophil differentiation culture with neutralizing antibodies\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods confirming CCR3 function in progenitor differentiation, single lab\",\n      \"pmids\": [\"12496441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CXCR3 ligands (CXCL9, CXCL10, CXCL11) inhibit CCR3-mediated functional responses (chemotaxis and Ca2+ flux) in human eosinophils and CCR3 transfectants induced by all three eotaxins; CXCL11 is the most efficacious antagonist. CCR3-CCR1 chimeric receptor studies revealed that CCL11 and CXCL11 share overlapping binding sites within CCR3 extracellular loops. Additionally, CCL11 binds with high affinity to CXCR3 (acting as a potential decoy receptor).\",\n      \"method\": \"Ca2+ flux assay; eosinophil chemotaxis assay; CCR3-CCR1 chimeric receptor constructs; radioligand binding\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — chimeric receptor mutagenesis combined with functional assays (Ca2+ flux, chemotaxis, binding) establishing overlapping binding sites\",\n      \"pmids\": [\"12884299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CCR3 ligation by eotaxin/CCL11 induces apoptosis in IL-2/IL-4-stimulated B cells via upregulation of CD95 and CD95L, triggering a caspase cascade; this apoptotic effect is distinct from chemotaxis (CCR3 ligation does not induce chemotaxis or adhesion in these cells).\",\n      \"method\": \"Flow cytometry; apoptosis assays; cytochrome c release measurement; caspase activity assays; CD95/CD95L expression analysis in primary B cells and B cell lines\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional and mechanistic assays in primary cells, single lab\",\n      \"pmids\": [\"12902471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CCR3 activation by eotaxin in bronchial epithelial cells (NCI-H292) leads to transactivation of EGFR (tyrosine phosphorylation of EGFR); EGFR inhibition (AG1478) blocks CCR3-induced MAP kinase phosphorylation and IL-8 production.\",\n      \"method\": \"Tyrosine phosphorylation assay; EGFR inhibitor (AG1478) treatment; MAP kinase phosphorylation assay; IL-8 ELISA\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection of CCR3-EGFR crosstalk with multiple downstream readouts, single lab\",\n      \"pmids\": [\"15219825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Eotaxin and CCR3-deficient mice show profound reduction of allergen-induced eosinophil recruitment to the airway lumen and loss of organized peribronchial/perivascular eosinophil accumulation; eotaxin-1/2 double-knockout approaches CCR3-deficiency levels, demonstrating a hierarchical and synergistic role for multiple CCR3 ligands in pulmonary eosinophilia.\",\n      \"method\": \"Genetic knockout mouse models (eotaxin-1, eotaxin-2, eotaxin-1/2 double KO, CCR3 KO); OVA-induced experimental asthma model; bronchoalveolar lavage analysis; tissue eosinophil counting\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — rigorous genetic epistasis with multiple knockout combinations, established experimental asthma model, multiple tissue compartments analyzed\",\n      \"pmids\": [\"16210640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CCR3 signaling mediates recruitment of eosinophils specifically to airway nerves (not overall tissue eosinophilia); CCR3 antagonist (GW701897B) prevented eosinophil clustering around nerves, preserved inhibitory M2 muscarinic receptor function, and abrogated airway hyperresponsiveness. Eotaxin is produced by airway parasympathetic neurons and is upregulated by IL-4 and IL-13.\",\n      \"method\": \"In vivo guinea pig antigen challenge model; CCR3 antagonist treatment; vagal stimulation assay; M2R function assay; immunostaining; cultured airway neurons + neuroblastoma cells with cytokine stimulation\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo pharmacological intervention with neurophysiological readouts, in vitro mechanistic follow-up in primary neurons\",\n      \"pmids\": [\"16374515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CCR3 is functionally expressed on asthmatic airway smooth muscle cells (ASMC) at higher levels than in non-asthmatic subjects; TNF-α increases CCR3 surface expression; eotaxin induces Ca2+ mobilization and significant chemotaxis of ASMC via CCR3.\",\n      \"method\": \"RT-PCR; FACS; Ca2+ assay; in vitro Boyden chamber chemotaxis assay; TNF-α stimulation\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays confirming CCR3 activity in primary ASMC, single lab\",\n      \"pmids\": [\"16081847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CCR3 activation in airway epithelial cells by eotaxins (CCL11, CCL24, CCL26) drives wound closure, cell proliferation, and chemotaxis; CCL11 also up-regulates profibrogenic molecules (FGF-1, FGF-5) and multiple CC/CXC chemokines; all effects are selectively inhibited by a CCR3 antagonist.\",\n      \"method\": \"In vitro wound repair assay; fluorometric proliferation and chemotaxis assays; pathway-specific cDNA arrays; CCR3 antagonist treatment\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays with pharmacological specificity control, single lab\",\n      \"pmids\": [\"16920975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"IL-13 transgenic lung overexpression-driven eosinophil recruitment and airway remodeling (mucus metaplasia, collagen deposition) require CCR3; CCR3-deficient mice crossed with IL-13 transgenics show 98% reduction in lung eosinophils and marked attenuation of remodeling, correlating with changes in pulmonary TGF-β1 and protease expression.\",\n      \"method\": \"Genetic cross of IL-13 lung-inducible transgenic mice with CCR3-deficient mice; histological and biochemical analysis of remodeling markers; eosinophil-deficient (ΔdblGATA) mouse controls\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — rigorous genetic epistasis with multiple knockout backgrounds, quantitative histology and molecular markers\",\n      \"pmids\": [\"17148674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Transmembrane residues Tyr-41, Tyr-113, and Glu-287 of CCR3 are critical for both antagonist (UCB35625) binding and receptor activation by CCL11/eotaxin; mutation Y113A abolishes antagonist binding and converts UCB35625 from antagonist to agonist; a novel specific CCR3 agonist (CH0076989) interacts with the same transmembrane residues and does not require the CCR3 N-terminus.\",\n      \"method\": \"Site-directed mutagenesis; CCR3-CCR1 chimeric receptor constructs; cell-based chemotaxis assay; Ca2+ flux assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — active-site mutagenesis with multiple mutants, chimeric receptors, and functional assays; single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"17635911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CCR3 is specifically expressed on choroidal neovascular endothelial cells in human AMD; genetic or pharmacological targeting of CCR3 or its eotaxin ligands inhibits injury-induced CNV in mice; CCR3 blockade directly inhibits endothelial cell proliferation and is uncoupled from eosinophil/mast cell inflammation.\",\n      \"method\": \"Immunohistochemistry on human AMD tissue; CCR3 gene knockout and pharmacological inhibition in mouse CNV models; endothelial proliferation assay; quantum dot in vivo imaging; comparison with eosinophil- and mast cell-deficient mice\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic and pharmacological CCR3 targeting, human tissue validation, mechanistic dissection using cell-type-deficient mice\",\n      \"pmids\": [\"19525930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CCL11 activates CCR3 on anaplastic large cell lymphoma (ALCL) cells in an autocrine manner, promoting cell survival via ERK1/2 phosphorylation and upregulation of anti-apoptotic proteins Bcl-xL and survivin; ERK inhibition completely blocked CCL11-promoted survival.\",\n      \"method\": \"Cell survival and proliferation assays; ERK1/2 phosphorylation (Western blot); anti-apoptotic protein expression; ERK inhibitor treatment; in vivo tumor growth assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple mechanistic assays (signaling, survival, in vivo) in cell lines, single lab\",\n      \"pmids\": [\"21406396\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CCR3-mediated secretion of eosinophil-associated RNases (EARs) in mouse and human eosinophils requires Gαi-dependent signaling through PI3K, ERK, and p38 MAPK; β1 and β2 integrins are also required, with cell spreading being obligatory for EAR secretion.\",\n      \"method\": \"RNase activity assay on primary mouse and human eosinophils; specific pathway inhibitors (PI3K, ERK, p38 MAPK inhibitors); integrin-blocking antibodies; microscopy for cell adhesion/spreading\",\n      \"journal\": \"Allergy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection of signaling pathway in primary cells from two species, single lab\",\n      \"pmids\": [\"23742707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CCL26 (eotaxin-3) induces CCR3 signaling in human dermal fibroblasts (which express CCR3 abundantly), resulting in intracellular Ca2+ mobilization, enhanced fibroblast migration, and wound repair capacity, but no proliferation; this provides a CCR3-mediated epidermis-to-dermis communication pathway in atopic skin inflammation.\",\n      \"method\": \"Flow cytometry and immunofluorescence for CCR3 on fibroblasts; Ca2+ mobilization assay; cell migration and repair assays; cell proliferation assay; real-time PCR for CCL26\",\n      \"journal\": \"Journal of dermatological science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays in primary fibroblasts, single lab\",\n      \"pmids\": [\"23702389\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Tyrosine sulfation of CCR3 N-terminal residues (specifically two sulfotyrosines in residues 8–23) dramatically enhances binding to CCL11/eotaxin-1; structural analysis reveals sulfotyrosine residues form hydrophobic, salt bridge, and cation-π interactions with conserved residues in CC chemokines. The orientation of CCR3 N-terminus relative to the chemokine differs substantially from CXC chemokine receptor complexes.\",\n      \"method\": \"NMR structure determination of CCL11 bound to sulfo-CCR3(8-23) peptide; functional receptor activity assays confirming intact CCR3 sulfation; binding affinity measurement\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — NMR structure with functional validation of sulfation, mechanistic insights into receptor-ligand recognition\",\n      \"pmids\": [\"25450766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Eotaxin-1 (CCL11) promotes prostate cancer cell invasion and migration via the CCR3-ERK pathway, leading to upregulation of MMP-3; siRNA knockdown of CCR3 inhibits invasion and attenuates eotaxin-1-induced ERK1/2 activation and MMP-3 expression; MEK inhibition (U0126) similarly suppresses invasion.\",\n      \"method\": \"siRNA knockdown of CCR3; invasion/migration assays; ERK1/2 phosphorylation (Western blot); MMP-3 mRNA (RT-PCR) and protein (ELISA); MEK inhibitor (U0126)\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA KD with multiple functional and signaling readouts, pharmacological pathway validation, single lab\",\n      \"pmids\": [\"24604010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CCL7 interacts with CCR3 in colon cancer cells to promote cellular proliferation, invasion, and migration via the ERK and JNK signaling pathways; CCL7-overexpressing cells formed faster ectopic tumors and developed liver/lung metastases in orthotopic mouse models.\",\n      \"method\": \"CCL7-overexpressing cell lines; in vitro proliferation, invasion, and migration assays; ectopic and orthotopic mouse models; signaling pathway analysis (ERK, JNK)\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo mechanistic experiments, single lab\",\n      \"pmids\": [\"27167205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CCL8 binds directly to CCR3 with a KD of ~1.2 × 10−7 M (measured by quartz crystal microbalance); CCL8 induces CCR3 internalization in vivo and has a weaker chemotactic effect compared to CCL11 and CCL24 on CCR3-expressing cells.\",\n      \"method\": \"Quartz crystal microbalance (QCM) binding assay; receptor internalization assay (flow cytometry); chemotaxis assay\",\n      \"journal\": \"BMC immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding measurement plus functional confirmation, single lab, biophysical approach\",\n      \"pmids\": [\"29281969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A peptide nanoparticle CCR3 antagonist (R321) binds directly to CCR3, inhibits only the early phase of ERK1/2 activation (not the late β-arrestin-associated phase), promotes CCR3 internalization and degradation (biased antagonism), and blocks eosinophil recruitment and airway hyperresponsiveness in a mouse asthma model.\",\n      \"method\": \"Dynamic light scattering; NMR binding analysis; flow cytometry; confocal microscopy; ERK1/2 Western blot (time-course); in vivo triple-allergen mouse asthma model\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct binding demonstrated by NMR, biased signaling established by time-resolved Western blot, in vivo validation in disease model\",\n      \"pmids\": [\"29778505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Cholesterol acts as a dose-dependent positive allosteric modulator of CCR3 function: increasing cholesterol concentration enhances CCR3 affinity for CCL11 (in both SMALPs and proteoliposomes), and this heightened receptor activation directly increases GTPase activity of the associated Gαi3 protein.\",\n      \"method\": \"Recombinant CCR3 production in E. coli; reconstitution into SMALPs and proteoliposomes; ligand affinity measurement; Gαi3 GTPase activity assay\",\n      \"journal\": \"Frontiers in molecular biosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro biochemical reconstitution with functional G-protein assay, single lab\",\n      \"pmids\": [\"34490352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cryo-EM structure of CCR3 in the apo state reveals that interactions around intracellular loop 2 (ICL2) of CCR3 are critical and conserved for G-protein activation; these interactions play a more critical role in G-protein coupling than those around ICL3.\",\n      \"method\": \"Cryo-electron microscopy; structure determination; functional mutagenesis experiments\",\n      \"journal\": \"Cell discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — cryo-EM structure complemented by functional mutagenesis experiments, rigorous structural biology approach\",\n      \"pmids\": [\"35570218\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Conditional knockout of bone marrow CCR3 in mice reduces eosinophilic inflammation and Th2 immune response in an OVA-induced allergic rhinitis model; this is mechanistically linked to inhibition of the PI3K/AKT signaling pathway downstream of CCR3.\",\n      \"method\": \"Cre-LoxP conditional knockout; OVA-induced AR mouse model; PI3K/AKT pathway inhibitor (Ly294002); histopathology; eosinophil counting; cytokine ELISA\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with pharmacological pathway confirmation, single lab\",\n      \"pmids\": [\"35354939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The CCL24/CCR3 axis stimulates M2 macrophage polarization and cardiac fibroblast activation via CCR3's G protein-coupled receptor function; blocking CCL24 prevents Ang II-induced cardiac hypertrophy and fibrosis; in vitro experiments confirmed CCL24 promotes activation and migration of cardiac fibroblasts via CCR3.\",\n      \"method\": \"Co-IP; ChIP; CCL24 antibody blockade in vivo (Ang II mouse model); single-cell CyTOF; in vitro fibroblast activation/migration assays; immunofluorescence co-localization\",\n      \"journal\": \"Cell biology and toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro mechanistic experiments with multiple methods, single lab\",\n      \"pmids\": [\"36131165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CCR3-expressing T cells in the periphery mediate age-related cognitive decline and neuroinflammation; CCR3 inhibition prevents infiltration of CCR3+ T cells across the blood-brain barrier, reducing neuroinflammation. The pro-cognitive benefit of CCR3 inhibition is not due to direct action on CNS-resident cells.\",\n      \"method\": \"CCR3 inhibition in aged mice; behavioral cognitive testing; T-cell infiltration analysis; blood-brain barrier assessment\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo pharmacological inhibition with mechanistic dissection distinguishing peripheral vs. central effects, single lab\",\n      \"pmids\": [\"36934154\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IgE directly promotes eosinophil migration in chronic rhinosinusitis by upregulating CCR3 expression on eosinophils; this effect is mediated through CD23 (FcεRII) on eosinophils, as lumiliximab (anti-CD23) restrains IgE-induced CCR3-dependent migration.\",\n      \"method\": \"Flow cytometry; immunohistochemistry/immunofluorescence; functional eosinophil migration assay; antibody blockade (omalizumab, lumiliximab)\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional migration assay with antibody blocking, mechanistic link between IgE/CD23 and CCR3, single lab\",\n      \"pmids\": [\"37922997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CCR3 mediates CCL7-induced neuronal hyperexcitability and ERK activation in trigeminal ganglion neurons; selective CCR3 antagonist (intra-TG injection) alleviates trigeminal neuropathic pain and reduces ERK phosphorylation; CCR3 is co-expressed with CCR2 on TG neurons.\",\n      \"method\": \"Real-time qPCR; immunofluorescence; Western blot (ERK phosphorylation); whole-cell patch clamp recording; selective receptor antagonists (intra-TG injection); behavioral pain testing\",\n      \"journal\": \"Molecular pain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — electrophysiology, pharmacological antagonism, and in vivo pain behavioral readouts, single lab\",\n      \"pmids\": [\"36998150\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CCR3 is a Gαi-coupled, seven-transmembrane CC chemokine receptor whose N-terminal sulfotyrosine residues (and extracellular loop 2) mediate high-affinity binding to eotaxins (CCL11, CCL24, CCL26) and other CC chemokines; upon ligand binding it couples to Gαi3 (allosterically potentiated by cholesterol), activates PI3K, ERK, p38 MAPK, and intracellular calcium signaling to drive eosinophil degranulation, chemotaxis, and EAR secretion; it is also expressed on Th2 lymphocytes, mast cells, airway epithelial and smooth muscle cells, dendritic cells, platelets, and vascular smooth muscle cells—mediating migration, wound repair, and remodeling in each—and functions as an HIV-1 co-receptor on CD4+ cells and microglia; transmembrane residues Tyr-41, Tyr-113, and Glu-287 are critical for both agonist activation and small-molecule antagonist binding, with ICL2 contacts being essential for G-protein coupling as revealed by cryo-EM.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CCR3 is a Gαi-coupled CC chemokine receptor that serves as the central effector receptor for eotaxins (CCL11/CCL24/CCL26) and related CC chemokines, driving eosinophil chemotaxis, degranulation, and tissue accumulation that underlie allergic and remodeling pathology [#5, #16]. High-affinity ligand engagement is governed by the receptor N-terminus: residues 1–35, and particularly two sulfotyrosines in the DDYY-containing region around residues 8–23, form the primary chemokine-binding surface through hydrophobic, salt-bridge, and cation-π contacts that are oriented distinctly from CXC-receptor complexes [#7, #26]. Agonist activation and small-molecule antagonist binding both converge on transmembrane residues Tyr-41, Tyr-113, and Glu-287, where the Y113A mutation can convert an antagonist into an agonist, while intracellular loop 2 contacts revealed by cryo-EM are the critical determinant of G-protein coupling [#21, #32]; cholesterol acts as a positive allosteric modulator that enhances CCL11 affinity and stimulates Gαi3 GTPase activity [#31]. Downstream, CCR3 signals through Gαi-dependent PI3K, ERK, and p38 MAPK, with cell spreading via β1/β2 integrins required for eosinophil RNase secretion, and EGFR transactivation contributing to MAP-kinase and IL-8 responses in epithelium [#24, #15]. Beyond eosinophils, functional CCR3 is expressed on Th2 cells, platelets, airway epithelial and smooth muscle cells, dermal fibroblasts, and vascular endothelium, where it mediates migration, wound repair, fibrosis, and neovascularization [#2, #9, #19, #22, #25], and on CD4+ cells and microglia it acts as an HIV-1 co-receptor whose usage depends on the gp120 V3 region [#0, #1]. Genetic eotaxin/CCR3 epistasis in mouse asthma models establishes its non-redundant requirement for allergen- and IL-13-driven airway eosinophilia and remodeling [#16, #20].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established that CCR3 has a function beyond chemokine signaling by acting as an HIV-1 entry co-receptor, defining a host-pathogen role for the receptor.\",\n      \"evidence\": \"CCR3/CD4 co-expression infectivity assay with eotaxin competition and V3-dependent isolate mapping\",\n      \"pmids\": [\"8674119\", \"8674120\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Restricted to a subset of HIV-1 isolates\", \"Physiological relevance relative to CCR5 in vivo not resolved\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Defined CCR3 co-receptor function in primary CNS cells, extending HIV-1 entry relevance to microglia.\",\n      \"evidence\": \"Primary microglial infection with anti-CCR3 antibody and eotaxin blocking\",\n      \"pmids\": [\"9024664\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of CCR3 versus CCR5 in CNS infection unquantified\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Showed CCR3 is selectively expressed on Th2 cells and functionally couples eotaxin to calcium flux and chemotaxis, linking the receptor to the Th2 axis of allergic immunity.\",\n      \"evidence\": \"Antibody-based Th2 isolation, Ca2+ measurement, and chemotaxis assays\",\n      \"pmids\": [\"9302298\", \"9480044\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional control of Th2-selective expression not addressed\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Determined that eosinophil degranulation is mediated exclusively through CCR3, separating effector (granule release) from generic calcium signaling and establishing CCR3 as the key eosinophil effector receptor.\",\n      \"evidence\": \"Ca2+ flux, eosinophil-derived neurotoxin RIA, and antibody blocking on purified eosinophils with multiple ligands\",\n      \"pmids\": [\"10984371\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling steps coupling CCR3 to granule exocytosis not defined here\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Mapped the eotaxin-binding surface to the CCR3 N-terminal region, providing the first structural basis for ligand recognition.\",\n      \"evidence\": \"Synthetic peptide binding screens and NMR characterization of the eotaxin–CCR3 N-terminus interface\",\n      \"pmids\": [\"10859315\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address transmembrane activation determinants\", \"Post-translational modification of the N-terminus not yet defined\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Extended functional CCR3 expression to platelets, broadening its role beyond leukocyte chemotaxis to hemostatic activation.\",\n      \"evidence\": \"RT-PCR, flow cytometry, Ca2+, aggregation/granule release assays with glycosaminoglycan cleavage\",\n      \"pmids\": [\"11110672\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo platelet relevance not established\", \"Single lab\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrated functional CCR3 on airway epithelium coupling eotaxin to pertussis-toxin-sensitive Gi signaling and tyrosine phosphorylation, implicating non-hematopoietic cells in CCR3 biology.\",\n      \"evidence\": \"Northern/Western blot, Ca2+ flux, tyrosine phosphorylation, radioligand binding, pertussis toxin and antibody blocking\",\n      \"pmids\": [\"11160184\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream transcriptional outputs not fully mapped here\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Revealed cross-regulation between chemokine systems by showing CXCR3 ligands antagonize CCR3 and that CCL11/CXCL11 share overlapping CCR3 extracellular binding sites.\",\n      \"evidence\": \"Ca2+ flux, chemotaxis, CCR3-CCR1 chimeric receptors, and radioligand binding\",\n      \"pmids\": [\"12884299\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological significance of cross-receptor antagonism in vivo unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Established the non-redundant, hierarchical requirement of CCR3 and its eotaxin ligands for allergen-induced airway eosinophilia using genetic epistasis.\",\n      \"evidence\": \"Eotaxin-1/2 and CCR3 knockout combinations in an OVA asthma model with BAL and tissue eosinophil counts\",\n      \"pmids\": [\"16210640\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-compartment-specific ligand contributions only partly resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Linked CCR3-driven eosinophil recruitment to airway nerves and M2 muscarinic dysfunction, connecting the receptor to airway hyperresponsiveness mechanistically.\",\n      \"evidence\": \"Guinea pig antigen challenge with CCR3 antagonist, vagal/M2R functional assays, and cytokine-stimulated neuron culture\",\n      \"pmids\": [\"16374515\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular signal for nerve-directed eosinophil clustering not defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed CCR3 is required for IL-13-driven airway remodeling, extending its role from cell recruitment to structural tissue changes.\",\n      \"evidence\": \"IL-13 transgenic × CCR3-deficient crosses with histology and ΔdblGATA eosinophil-deficient controls\",\n      \"pmids\": [\"17148674\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether remodeling is fully eosinophil-dependent versus direct CCR3 action unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified the transmembrane residues (Tyr-41, Tyr-113, Glu-287) shared by agonists and antagonists, defining the small-molecule pharmacophore and an agonist/antagonist switch at Y113.\",\n      \"evidence\": \"Site-directed mutagenesis, CCR3-CCR1 chimeras, chemotaxis and Ca2+ assays\",\n      \"pmids\": [\"17635911\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution ligand-bound structure at the time\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Uncovered an eosinophil-independent CCR3 role on choroidal neovascular endothelium, repositioning the receptor as a target in age-related macular degeneration.\",\n      \"evidence\": \"Human AMD immunohistochemistry, mouse CNV genetic/pharmacological targeting, endothelial proliferation assays, cell-type-deficient mouse controls\",\n      \"pmids\": [\"19525930\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endothelial CCR3 signaling pathway in angiogenesis not detailed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined the Gαi→PI3K/ERK/p38 signaling and integrin-dependent spreading required for CCR3-driven eosinophil RNase secretion, mapping the effector signaling cascade.\",\n      \"evidence\": \"RNase activity assays in mouse and human eosinophils with pathway inhibitors and integrin-blocking antibodies\",\n      \"pmids\": [\"23742707\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Spatial coordination of integrin and CCR3 signaling not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established that tyrosine sulfation of the CCR3 N-terminus is a critical determinant of high-affinity eotaxin binding, defining a post-translational regulatory layer of ligand recognition.\",\n      \"evidence\": \"NMR structure of CCL11 bound to sulfo-CCR3(8-23) with functional sulfation validation\",\n      \"pmids\": [\"25450766\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Regulation of CCR3 sulfation in vivo not addressed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated biased antagonism of CCR3, showing a peptide nanoparticle can selectively inhibit early ERK signaling while promoting receptor internalization, refining therapeutic targeting concepts.\",\n      \"evidence\": \"NMR binding, time-resolved ERK Western blot, confocal internalization, and in vivo allergen asthma model\",\n      \"pmids\": [\"29778505\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"β-arrestin-associated late signaling consequences in disease not fully mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified cholesterol as a positive allosteric modulator coupling membrane lipid environment to CCR3 ligand affinity and Gαi3 GTPase output.\",\n      \"evidence\": \"Reconstituted recombinant CCR3 in SMALPs/proteoliposomes with affinity and Gαi3 GTPase assays\",\n      \"pmids\": [\"34490352\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro reconstitution only\", \"Cellular cholesterol modulation of CCR3 not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Provided a cryo-EM structure establishing ICL2 as the principal determinant of CCR3 G-protein coupling, defining the activation architecture.\",\n      \"evidence\": \"Apo-state cryo-EM structure with functional mutagenesis\",\n      \"pmids\": [\"35570218\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No ligand- or G-protein-bound active-state structure reported here\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CCR3's broad non-eosinophil functions (endothelial angiogenesis, fibroblast/cardiac fibrosis, tumor invasion, neuronal hyperexcitability, age-related cognitive decline) are encoded by distinct ligand-, cell-type-, or biased-signaling programs remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-type-specific downstream signaling not unified\", \"Whether distinct ligands (CCL7, CCL8, CCL24, CCL26) bias different outcomes is unclear\", \"Active-state structures with diverse ligands lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [2, 5, 10, 21]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [31]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 10, 21, 32]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [24, 31, 32]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 5, 16]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 22]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CCL11\", \"CCL24\", \"CCL26\", \"CCL7\", \"CCL8\", \"GNAI3\", \"CD4\", \"EGFR\"],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}